%0 Journal Article
%A Mallardo, Domenico
%A Woodford, Rachel
%A Menzies, Alexander M
%A Zimmer, Lisa
%A Williamson, Andrew
%A Ramelyte, Egle
%A Dimitriou, Florentia
%A Wicky, Alexandre
%A Wallace, Roslyn
%A Mallardo, Mario
%A Cortellini, Alessio
%A Budillon, Alfredo
%A Atkinson, Victoria
%A Sandhu, Shahneen
%A Olivier, Michielin
%A Dummer, Reinhard
%A Lorigan, Paul
%A Schadendorf, Dirk
%A Long, Georgina V
%A Simeone, Ester
%A Ascierto, Paolo A
%T The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
%J Journal of translational medicine
%V 21
%N 1
%@ 1479-5876
%C London
%I BioMed Central
%M DKFZ-2023-02168
%P 753
%D 2023
%X The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in melanoma tissue from patients with type 2 diabetes.To evaluate the impact of diabetes on oncological outcomes of patients with advanced melanoma treated with nivolumab plus the LAG3 inhibitor relatlimab we performed a retrospective multicenter study.Overall, 129 patients were included: 88 without diabetes before the treatment, 37 who were diagnosed with type 2 diabetes before the start of treatment, and 4 without diabetes before treatment who developed immune checkpoint inhibitor-induced diabetes (ICI-DM). PFS was 21.71 months (95
%K Diabetes (Other)
%K LDH (Other)
%K Melanoma (Other)
%K Nivolumab + relatlimab (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37880788
%R 10.1186/s12967-023-04607-4
%U https://inrepo02.dkfz.de/record/284984